Skip to content

Botulinum Toxin Injection in Reducing Scar Following Cheilorrhaphy.

Efficacy of Botulinum Toxin Injection in Reducing Scar Following Cheilorrhaphy: A Randomized Controlled Clinical Trial.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07137234
Enrollment
32
Registered
2025-08-22
Start date
2025-03-15
Completion date
2026-05-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unilateral Cleft Lip

Keywords

botulinum toxin, cleft lip, scar

Brief summary

the aim of the study will be directed to evaluate clinically the effect of botulinum toxin type A injection on reducing the scar following cleft lip surgical repair.

Interventions

PROCEDUREModified Millard rotation advancement flap technique

the cleft is repaired by surgical intervention

DRUGbotulinum toxin injection (BTX A) before surgical intervention

the patient will receive Botulinum toxin type A followed by surgical closure of cleft lip

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Weeks to No maximum
Healthy volunteers
No

Inclusion criteria

: * patients with mild to severe unilateral cleft lip requiring repair * free from any systemic disease * with or without cleft palate * fit for general anesthesia

Exclusion criteria

: * patients with syndromic type of cleft lip * patients with systemic disease

Design outcomes

Primary

MeasureTime frameDescription
Scar width3 and 6 months follow upScar width will be measured by independent examiners at two at two certain points using caliper: point 1 (Bottom) :above the white roll. point 2 (Top): below the nasal sill.

Secondary

MeasureTime frameDescription
Vancouver scar scale3 and 6 monthsit evaluates four factors: pigmentation, pliability, height, and vascularity. it is used to asses treatment.

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORBasel Saeed Shamaa, Master's

Mansoura University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026